Triumpharma Inc. is a pioneer in developing systems and solutions for advanced drug delivery. We strive to bridge the gap between life science and modern healthcare.

Triumpharma Inc. develops technologies that enhance the performance of many of today's commonly available pharmaceutical products and new chemical entities that give raise to challenging bioavailability problems.

Triumpharma has strong technical capabilities to take products from feasibility to pilot scale. Triumpharma conducts formulation optimization studies, pre-clinical trials on animals, human clinical studies including bioavailability/ bioequivalence trial complying with the international guidelines.

The company's core advantages are its extremely low-cost base, experienced staff with multi national experience, holding PhDs from western universities, high-quality research, a large pool of patient’s and volunteers, and fast formulation development meeting the necessary regulatory requirements.

Meet Dr. Al-Ghazawi

Triumpharma Founder and CEO

Dr. Ahmed Al-Ghazawi has over 18 years of experience in the pharmaceutical sector. He has worked with Merck and GlaxoSmithKline for over seven years as a pharmaceutical scientist, later became the technical and development manager responsible for directing, designing, and development of new and existing Merck drug delivery systems (DDS). Prior to joining SmithKline he was a senior pharmaceutical scientist at Norton Healthcare for nearly 4 years and have been involved in designing and developing of a novel dry powder inhaler and breath operated inhaler that won Prince Charles's Award for Innovation in UK,1996.

Dr. Al-Ghazawi is a member of the American Association of Pharmaceutical Scientist (AAPS); USA, the Controlled Release Society Inc.; USA, the Royal Pharmaceutical Society of Great Britain – Academy of Pharmaceutical Sciences and The Aerosol Society; UK. Dr Al-Ghazawi was a visiting lecturer teaching 2/3-year pharmaceutical chemistry students for 1998-1999 courses at the University of Kent, Canterburry, UK.

Dr. Al-Ghazawi is an inventor/co-inventor of many patents in drug delivery systems. One of his patents covers Paroxetine salt, an antidepressant drug. Paxil® (Paroxetine HCl) sells at $2.2 billion in the USA annually. Dr Al-Ghazawi received his PhD from the School of Pharmacy, University of London,-UK, B.Pharm., from Jordan University of Science and Technology- Jordan and his high school Diploma from the USA.

To provide high quality services to the pharmaceutical and biotechnology companies on time while maintaining quality, with competitive prices.

We take pride in providing internationally renowned distinguished and integrated pharmaceutical services for Research & Development, following the highest quality standards, gaining international accreditation using state of the art techniques and unique information technologies.

All while remaining committed to the fast execution precision and safeguard the participants' health and safety, promoting our human resources and services, to meet our clients' high expectations and we, together, contribute to build healthier and safer environment.

  • Credibility
  • Participation
  • Taking Responsibilities
  • Creativity and Innovation
  • Transparency and Clarity
  • Learning
  • Quality
  • Achievement
  • Team Work
  • Acceptance of Criticism
  • Excellence

Experienced scientists in pharmaceutics, biopharmaceutics, pharmacokinetics, clinical pharmacology, toxicology & immunology, pharmaceutical technology and drug delivery systems, statistics, medicinal and analytical chemistry and medical doctors-for clinical trials. The company has access and collaborates with high caliber experts in several academic institutions, clinical and research centers, hospitals, and professional organizations based locally and internationally.

The people working with Triumpharma projects are internationally recognized physician-scientists with comprehensive experience in drug development and clinical trials with wide range of drug classes.

Triumpharma Facility

The facility of Triumpharma is located in Amman-Jordan In the vicinity of Jordan Universities, major hospitals and the Ministry of Higher Education. It is a state-of-the-art purpose built R&D facility in compliance with GMP, GLP, and GCP. The R&D Facility is over 25,000 ft2 and has the capacity to house up to 80-100 employees. It serves as both the R&D and corporate headquarters of the company.

This publication has been produced with the assistance of the European Union in cooperation with Jordan Enterprise Development Corporation. *

* The contents of this publication are the sole responsibility of Triumpharma and can in no way betaken to reflect the views of the European Union & Jordan Enterprise Development Corporation